GMU's Petricoin Building Database That Details Activation in Cancer Protein Pathways
August 13, 2010
GMU's Petricoin Building Database That Details Activation in Cancer Protein Pathways
Petricoin said the database could help physicians make better treatment decisions, aid pharmaceutical firms' drug-development efforts, and uncover new indications for existing therapies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Duke Team Identifies Phosphoprotein Signatures That Could Predict Breast Cancer Risk
November 12, 2010 / ProteoMonitor - Theranostics Health to Launch Breast Cancer Dx in Early 2013, Raise $5M to $10M in Funding
June 15, 2012 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release
May 3, 2013 / ProteoMonitor - Theranostics Looks for Med Fusion Deal to Aid in Clinical Validation, Payor Access
August 31, 2012 / ProteoMonitor